UCSF Clinical Trials

Currently Enrolling:

CC#10993: Phase 1/2 of mTOR Inhibitor CC-223 in Advanced Solid Tumors, NHL or Multiple Myeloma (Patients with neuroendocrine tumors may be eligible) Contact: Anne Reinert, NP (415) 415-353-9291: This email address is being protected from spambots. You need JavaScript enabled to view it.

CC# 114520: Phase II Study of Axitinib in Patients with Advanced Carcinoid Tumors (MCC #16438) Contact: Adrienne Brenner (415) 353-9544: This email address is being protected from spambots. You need JavaScript enabled to view it.

CC#08451-B: Safety profile assessment of theraspheres used for treatment of metastatic liver disease from primary colorectal, NET, melanoma, & breast cancers refractory to chemo Contact: Kimberly Morrell or Leslie Lind (415) 353-1300 This email address is being protected from spambots. You need JavaScript enabled to view it. or This email address is being protected from spambots. You need JavaScript enabled to view it.

Pending Studies:

CC# 124521: A Phase 3, Randomized, Placebo-controlled, Parallelgroup, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome Refractory to Somatostatin Analog (SSA) Therapy Contact: Ryan Courtin (415) 353-7284: This email address is being protected from spambots. You need JavaScript enabled to view it.

Alliance A021202: Prospective Randomized Phase II Trial of Pazopanib (NSC #737754, IND #75648) Versus Placebo in Patients with Progressive Carcinoid Tumors Contact: Regina Linetskaya (415) 353-7145: This email address is being protected from spambots. You need JavaScript enabled to view it.

UCSF

There are no articles in this category. If subcategories display on this page, they may have articles.